Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:45 AM
Ignite Modification Date:
2025-12-25 @ 12:45 AM
NCT ID:
NCT03115567
Eligibility Criteria:
Inclusion Criteria:
* Patients must have a histologically or cytologically confirmed cancer diagnosis for which EGFRI treatment is indicated
* Initiation of topical steroids or control treatment within 3 days of initiation of cetuximab, erlotinib, panitumumab, or afatinib
* Patients must be age ≥ 18 years.
* Life expectancy of greater than 6 weeks
* Patient able to use topical medications reliably and complete questionnaires with assistance if needed
* Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study.
Exclusion Criteria:
* Patients who have used systemic or topical steroids within 7 days of trial registration, or start systemic or topical steroids for reasons unrelated to trial during the 6-week follow up period
* Patients who have used antibiotics within 7 days of trial registration, or start antibiotics for other conditions during the 6-week follow up period
* History of allergic reactions to topical steroids
* Patients with any rash at the time of study registration
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Patients using any other topical medications in the treatment areas (face, chest, or back).
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03115567
Study Brief:
Protocol Section:
NCT03115567